

WEB TABLE I TRIALS EVALUATING THE IMMUNOGENICITY AND PROTECTIVE EFFICACY OF TYPHOID CONJUGATE VACCINES

Type of typhoid conjugate vaccine	Author (y) [Ref.]	Country of study	Year of study	Age of the subjects	Sample size		Follow-up duration	Seroconversion rate/protective efficacy at the end of follow-up period (%)
					Vaccine	Placebo		
<i>Seroconversion rate</i>								
Vi-CRM197	Bhutta, <i>et al.</i> (2014)[30]	India, Pakistan, Philippines	2011-12	Infants: 6 to 8 weeks Older infants: 9 to 12 mo Children: 24 to 59 mo Adults: 18 to 45 y	40 (in each age group)	40 (in each age group)	6 mo	Infants: 25-70* Older Infants: 70-89* Children: 90-95* Adults: 85-95*
Vi-TT	Mohan, <i>et al.</i> (2015)[17]	India	2011-12	Open label cohort: 6 mo to 23 mo	Open label cohort (no controls) 327		2 y 5 y	65.1 (56.1-73.4) 84.1 (76.6-90)#
	WHO (2017)[12]			Double blinded, RCT 2 to 45 y	Double blinded, RCT 340 314		2 y 5 y	79.8 (69.6-87.8) 92.9 (85.1-97.3)#
	Mitra, <i>et al.</i> (2015)[16]	India	2012	6 mo to 12 y	905	860	1 y	6 months to 2 years: 100 2 years to 5 years: 88.9 5 years to 12 years: 81.6
	Jin, <i>et al.</i> (2017)[15]	UK	2015-16	18 to 60 y	41	34	1 mo	100
<i>Protective efficacy</i>								
Vi-rEPA	Lin, <i>et al.</i> (2001) [30] Lanh, <i>et al.</i> (2003)[31]	Vietnam	1998-2002	2 to 5 y	5991	6017	27 mo 46 mo	91.5 (77.1-96.6) 89 (76-96.9)
Vi-TT	Mitra, <i>et al.</i> (2016) [16]	India	2012	6 mo to 12 y	905	860	1 y	100 (97.6-100)
	Jin, <i>et al.</i> (2017)[15]	UK	2015-16	18 to 60 y	41	34	1 mo	54.6 (26.7-71.8)

\*Seroconversion rates are presented as range; #5 year seroconversion rates observed after a booster dose at 720 days; RCT: randomized controlled trial.